United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤ 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: pregnancy category c. studies performed in pregnant rats and rabbits given carvedilol revealed increased post-implantation loss in rats at doses of 300 mg/kg/day [50 times the maximum recommended human dose (mrhd) as mg/m2 ] and in rabbits at doses of 75 mg/kg/day (25 times the mrhd as mg/m2 ). in the rats, there was also a decrease in fetal body weight at the maternally toxic dose of 300 mg/kg/day (50 ti

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets, usp are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets, usp are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol tablets. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy.

United States - English - NLM (National Library of Medicine)

direct rx - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 6.25 mg - 1.1 heart failure carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4) and clinical studies (14.1)]. 1.2 left ventricular dysfunction following myocardial infarction carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)]. 1.3 hypertension carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)]. carvedilol tablets are contraindica

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; povidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; povidone; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; povidone; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carvedilol 12.5mg;   - tablet - 12.5 mg - active: carvedilol 12.5mg   excipient: colloidal silicon dioxide crospovidone iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose povidone - carvedilol sandoz is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carvedilol 25mg;   - tablet - 25 mg - active: carvedilol 25mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone - carvedilol sandoz is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carvedilol 6.25mg;   - tablet - 6.25 mg - active: carvedilol 6.25mg   excipient: colloidal silicon dioxide crospovidone iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose povidone - carvedilol sandoz is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).